Company Overview and News

 
TM may lose FBM KLCI constituent stock status

5h thestar.com.my
Downtrend: TM shares fell six sen, or 2.34, to close at RM2.50 yesterday. At that price, TM’s market cap stood at RM9.4bil, compared with RM22.69bil at the start of the year. — Bernama
TGLVY 4863 7113 TPGVF MYTEF 5246 GEBHF 7277

 
Telekom Malaysia may drop out from FBM KLCI, says CIMB Research

2018-10-18 theedgemarkets
KUALA LUMPUR (Oct 18): CIMB IB Research said Telekom Malaysia Bhd could be excluded as a constituent stock while Top Glove Corp Bhd may be added when FTSE Russel announces the outcome of ist semi-annual review of the FBM KLCI constituents on Dec 6 this year.
TGLVY 4863 7113 TPGVF MYTEF 5246 GEBHF 7277

 
KLCI gains after US equities' overnight rise

2018-10-17 theedgemarkets
KUALA LUMPUR (Oct 17): The FBM KLCI gained 3.75 points or 0.22% today with Asian shares after US equities' overnight rise.
HLFBF 3867 5819 1082 BATS 4162 2836 5246

 
KLCI off to muted start as key Maybank, CIMB drag

2018-10-16 theedgemarkets
KUALA LUMPUR (Oct 16): The FBM KLCI started off on a muted note this morning against teh backdrop of modest gains at regional markets, as key index-linked heavyweights dragged.
5183 MLYBY PECGF MLYNF BATS 4162 5246 7022 9059 CIMDF GBTKF 1155 1023

 
Westports buys land below sea from PKNS to expand terminal

2018-09-14 theedgemarkets
KUALA LUMPUR: Westports Holdings Bhd is buying a parcel of land below sea, measuring 154.2 hectares, off Pulau Indah in Selangor from Perbadanan Kemajuan Negeri Selangor (PKNS) for RM116.19 million cash.
5246 BSMAF 1818

 
Westports buys undersea land from PKNS for RM116mil

2018-09-14 thestar.com.my
Westports said the land would be used to expand the container terminals, as the current preliminary port design for Container Terminal 10 to Container Terminal 19 required additional land acreage to accommodate new wharf and container yard space to facilitate effective operations of the new container terminals.
5246 BSMAF 1818

 
KLCI seen trending sideways ahead of extended weeekend, support at 1,777

2018-09-13 theedgemarkets
KUALA LUMPUR (Sept 14): The FBM KLCI is seen trending sideways ahead of the extended weekend immediate support at 1,777.
5657 8338 6888 AXXTF 5246 5584

 
Westports, BAuto, Yee Lee, Tasco, SMTrack, Panpages, Axiata, FGV, Binasat, Parkson and Dataprep

2018-09-13 theedgemarkets
KUALA LUMPUR (Sept 13): Based on corporate announcements and news flow today, stocks in focus on Friday (Sept 14) may include: Westports Holdings Bhd, Bermaz Auto Bhd, Yee Lee Corp Bhd, Tasco Bhd, SMTrack Bhd, Panpages Bhd, Axiata Group Bhd, FGV Holdings Bhd, Binasat Communications Sdn Bhd, Parkson Holdings Bhd and Dataprep Holdings Bhd.
PKSGF PTXAF 3368 5246 5584 5657 PKSGY 8338 6888 PTXKY AXXTF BSMAF 1818

 
Westports to acquire undersea land from PKNS for RM116.185m

2018-09-13 malaymail
KUALA LUMPUR, Sept 13 — Westports Holdings Bhd’s wholly-owned subsidiary, Westports Malaysia Sdn Bhd (WMSB), is acquiring 154.2 hectares of undersea land in Pulau Indah, Selangor from the Selangor State Development Corporation (PKNS) for RM116.185 million in cash.
5246 BSMAF 1818

 
Westports buys land below sea from PKNS for RM116.19m to expand container terminal

2018-09-13 theedgemarkets
KUALA LUMPUR (Sept 13): Westports Holdings Bhd is buying a parcel of land below sea, measuring 381 acres (154.2 hectare), off Pulau Indah in Selangor from Perbadanan Kemajuan Negeri Selangor (PKNS) for RM116.19 million cash.
5246 BSMAF 1818

 
Stock market could be volatile in the months ahead, says CIMB Research

2018-09-05 theedgemarkets
KUALA LUMPUR (Sept 5): CIMB IB Research said August was a good month for the KLCI as the market ended on a positive note despite disappointing 2Q GDP growth and a soft corporate earnings season but said the stock market could be volatile in the months ahead.
5246 GEBHF 7277

 
KLCI struggles to recoup losses, stages marginal recovery

2018-08-14 theedgemarkets
KUALA LUMPUR (Aug 14): The FBM KLCI struggled to recoup some lost ground in the morning session today amid some choppy trading.
7047 BATS 4162 5246 5202 9334 6033 7233 2852 5029 PNADF 5347 5225 7668 6645 TNABY TNABF Q0F IHHHF PNAGF

 
Westports expected to enjoy higher gateway tariffs

2018-08-14 theedgemarkets
Westports Holdings Bhd (Aug 13, RM3.62) Downgrade to hold with a target price (TP) of RM4.01: Westports Holdings Bhd announced that the Port Klang Authority (PKA) had deferred the impending container tariff revision by six months to March 1, 2019 instead of Sept 1, 2018. On average, tariffs were slated for a 13% increase. Aside from the previous tariff hike of a similar quantum in November 2015, the last revision stretched back to 2001.
5246

 
Westports shares tumble on tariff hike delay

2018-08-14 thestar.com.my
PETALING JAYA: Shares of Malaysia’s largest port operator Westports Holdings Bhd fell, following news that the second phase of a tariff hike will be delayed for six months until March next year.
5246

 
KLCI tumbles 1.13% as regional sentiment takes a beating

2018-08-13 theedgemarkets
KUALA LUMPUR (Aug 13): The FBM KLCI tumbled 1.13% at the midday break today as sentiment took a beating and key blue chips on Bursa Malaysia fell in tandem with the regional markets.
7036 5246 9334 6033 7123 PNADF 5347 5225 3301 0026 TNABY 5819 TNABF Q0F BSMAF IHHHF PNAGF 1818

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...